Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 21, 2022 16:59 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
November 14, 2022 16:01 ET
|
Harpoon Therapeutics
HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing...
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
November 03, 2022 09:09 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
October 04, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the...
Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
September 19, 2022 16:05 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
September 01, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 16:01 ET
|
Harpoon Therapeutics
Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
August 02, 2022 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...